About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Have a good wkend Driver...relax!
kim

m_dwane
Yes, it genuinely does look good.
kim

That was quick the placing has taken place already.

PLACING RAISES 1.2 MILLION

Chairman, John Pool, said:

'I would like to thank all shareholders for their insight and support.
We are proud of what this company has achieved and believe that EiRx has
extraordinary science and potential. We look forward to announcing developments over the coming months.'

http://moneyam.uk-wire.com/cgi-bin/articles/200603311645058094A.html

"We look forward to announcing developments over the coming months.' Yes so are we.

good start to the week. and MDY up as well.

mp
You spoke to soon mdy is now also down, still early days on this one I will be adding.

Lots of buying in the past hour soon be blue by the looks of it.

looks very good, driver...it has a good future

There will be a lot of shares shifted over the next few days I would think, a good time to buy more or just sit tight and wait for a nice blue colour by the end of the week.
kim

I topped up yesterday on the dip, ERX is very active lots of volume today.

1/2M traded today and the sp stands still, MMMmm.

I wouldn't expect much sp movement until all of the 603m shares have been soaked up Driver.
kim

Explains the action today.

D/Express Artical today

Drug discovery company Eirx therapeutics, which is developing therapies for cancer and has just raised 1.2 million through a placing, eased 0.02p to 0.026p amid speculation a deal with a Danish company was imminent.

I don't know anything about Danish drug companies other than the company ZGene, which is developing cancer drugs - could be them, but have no idea really. That should not detract from the sp long term.
kim

sounds as though rewards are on the horizon-this is probably the reason the share placing hasn't knocked them more.

Lets not forget why we invested in ERX I topped up today.

EiRx passed an important milestone in August 2005 with the filing of the company's first patents covering distinct chemical compounds that may be useful in the treatment of cancer. These drug candidates were identified using the Company's EnPADTM screening technology, which enables the discovery of compounds that specifically target the cell survival pathways relied upon by tumours for continued growth and viability. In January of 2006, the Company announced a second patent application describing another series of compounds identified with the use of EnPADTM. Both these patent applications describe series of novel compounds that selectively kill colorectal and breast cancer cells in vitro.

With the benefit of the anticipated new funds I am confident that EiRx can progress to secure proof of concept for the leading compounds in our pipeline, creating a solid basis for future partnering activities.

This is one of my two blues today the rest are RED good old erx.

Renewed interest may be some news soon?

Hope so-just back from 2 weeks in Majorca-not much contact with the market so very glad to be out of the turmoil! glad to see erx and hml are holding up not so impressed with PCM without the bid tv deal how much of a business do they have?? not much I can salvage so will have to hold on-also a bit sick to have sold 30000 TTC shares before going away and missed out on the takeover when will I learn not to be hasty!!

mp
Hope you had a good time best place to be with the ftse in a dive pcm we will have to hold I'm afraid and see what happens.

Topped up today the sp could move very fast with some news that could appear at any time.

There could be strong news flow as three or four compounds move along the drug discovery cycle.
Large Pharma competition pushing licensing activity to earlier stages of development
Focus on cancer is lucrative in terms of both licensing deals and M&A activity.
Also big Pharma can look to acquire cancer companies for access to product pipeline.
Discussion with major pharmas can be convoluted and a number of such discussions to secure out licensing agreements are on going.